Jonathan Lim is­n't ready to say much about his new start­up, but he does have $42M for it

Jonathan Lim knows how to build biotechs for a sale. He auc­tioned off Igny­ta — where he was CEO — to Roche last Feb­ru­ary for a tidy $1.7 bil­lion, gain­ing a 74% pre­mi­um on his stock. A few months be­fore he al­so par­tic­i­pat­ed in the sale of Bon­ti to Al­ler­gan, which he had co-found­ed and helped man­age as chair­man of the board.

Now he’s on to a new start­up, but don’t look for a lot of de­tails about the plans he’s hatch­ing now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER